Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideGILDGilead Sciences
FinDog View：Neutral
| Metric | GILD | MRNA |
|---|
| Close | 170.68 | 221.72 |
| Market Cap | $213B | $88.3B |
| 1M | +14.51% | +15.14% |
| P/E (TTM) | — | — |
| Forward P/E | 22.0 | — |
| P/E 5-Yr Percentile | — | — |
| P/S | 7.0 | 39.7 |
| P/B | 17.9 | 13.1 |
| Dividend Yield | 3.98% | — |
| Latest Quarter Revenue | $8.3B | $145M |
| Revenue YoY | +6.8% | +2.1% |
| Gross Margin | 81.1% | 35.9% |
| Latest Quarter EPS | 1.94 | -1.97 |
| Avg Post-Earnings Move | ±3.8% | ±4.2% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.57% | — |
| 90-Day Net Insider Buying | −$15.9M | −$62.6M |
GILD · Revenue, Last 8 Quarters ($B)
MRNA · Revenue, Last 8 Quarters ($B)
